Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Celularity (NASDAQ: CELU) announced a publication in Frontiers in Immunology on April 4, 2025, focusing on the relationship between senescence, Natural Killer (NK) cells, and cancer. The publication explores how aging affects the immune system's fight against cancer and highlights the role of senoablative NK cells in disease progression.
The research emphasizes the importance of maintaining NK cell function for healthy aging and discusses the potential of adoptive NK cell therapy to counter immunosenescence. The company's clinical-stage candidate CYNK-001, a placental-derived allogeneic NK cell therapy, has been studied in over 70 subjects with acceptable safety profiles. The therapy aims to eliminate senescent cells that release toxic cytokines promoting inflammation and malignant transformation, potentially benefiting conditions like age-related frailty and sarcopenia.
Celularity (NASDAQ: CELU) ha annunciato una pubblicazione su Frontiers in Immunology il 4 aprile 2025, incentrata sulla relazione tra senescenza, cellule Natural Killer (NK) e cancro. La pubblicazione esplora come l'invecchiamento influisca sulla lotta del sistema immunitario contro il cancro e mette in evidenza il ruolo delle cellule NK senoablative nella progressione della malattia.
La ricerca sottolinea l'importanza di mantenere la funzionalità delle cellule NK per un invecchiamento sano e discute il potenziale della terapia con cellule NK adottive per contrastare l'immunosenescenza. Il candidato in fase clinica dell'azienda, CYNK-001, una terapia con cellule NK allogeniche derivate dalla placenta, è stato studiato in oltre 70 soggetti con profili di sicurezza accettabili. La terapia mira a eliminare le cellule senescenti che rilasciano citochine tossiche che promuovono l'infiammazione e la trasformazione maligna, beneficiando potenzialmente condizioni come la fragilità legata all'età e la sarcopenia.
Celularity (NASDAQ: CELU) anunció una publicación en Frontiers in Immunology el 4 de abril de 2025, centrada en la relación entre la senescencia, las células Natural Killer (NK) y el cáncer. La publicación explora cómo el envejecimiento afecta la lucha del sistema inmunológico contra el cáncer y destaca el papel de las células NK senoablativas en la progresión de la enfermedad.
La investigación enfatiza la importancia de mantener la función de las células NK para un envejecimiento saludable y discute el potencial de la terapia adoptiva con células NK para contrarrestar la inmunosenescencia. El candidato en etapa clínica de la empresa, CYNK-001, una terapia con células NK alogénicas derivadas de placenta, ha sido estudiado en más de 70 sujetos con perfiles de seguridad aceptables. La terapia tiene como objetivo eliminar las células senescentes que liberan citoquinas tóxicas que promueven la inflamación y la transformación maligna, beneficiando potencialmente condiciones como la fragilidad relacionada con la edad y la sarcopenia.
Celularity (NASDAQ: CELU)는 2025년 4월 4일 Frontiers in Immunology에 노화, 자연 살해 세포(NK 세포) 및 암의 관계에 관한 발표를 했습니다. 이 출판물은 노화가 면역 시스템의 암과의 싸움에 어떤 영향을 미치는지를 탐구하고, 질병 진행에서의 NK 세포의 역할을 강조합니다.
연구는 건강한 노화를 위해 NK 세포 기능을 유지하는 것의 중요성을 강조하고, 면역 노화에 대응하기 위한 NK 세포 채택 요법의 잠재력을 논의합니다. 회사의 임상 단계 후보인 CYNK-001, 태반 유래 동종 NK 세포 요법은 70명 이상의 피험자에서 안전성 프로필이 허용 가능한 것으로 연구되었습니다. 이 요법은 염증과 악성 변화를 촉진하는 독성 사이토카인을 방출하는 노화 세포를 제거하는 것을 목표로 하며, 노화 관련 허약 및 근감소증과 같은 상태에 잠재적으로 도움이 될 수 있습니다.
Celularity (NASDAQ: CELU) a annoncé une publication dans Frontiers in Immunology le 4 avril 2025, axée sur la relation entre la sénescence, les cellules Natural Killer (NK) et le cancer. La publication explore comment le vieillissement affecte la lutte du système immunitaire contre le cancer et met en lumière le rôle des cellules NK senoablatives dans la progression de la maladie.
La recherche souligne l'importance de maintenir la fonction des cellules NK pour un vieillissement en bonne santé et discute du potentiel de la thérapie par cellules NK adoptives pour contrer l'immunosénescence. Le candidat en phase clinique de l'entreprise, CYNK-001, une thérapie par cellules NK allogéniques dérivées du placenta, a été étudié chez plus de 70 sujets avec des profils de sécurité acceptables. La thérapie vise à éliminer les cellules sénescentes qui libèrent des cytokines toxiques favorisant l'inflammation et la transformation maligne, bénéficiant potentiellement à des conditions telles que la fragilité liée à l'âge et la sarcopénie.
Celularity (NASDAQ: CELU) gab am 4. April 2025 eine Veröffentlichung in Frontiers in Immunology bekannt, die sich mit der Beziehung zwischen Seneszenz, natürlichen Killerzellen (NK-Zellen) und Krebs befasst. Die Veröffentlichung untersucht, wie das Altern das Immunsystem im Kampf gegen Krebs beeinflusst und hebt die Rolle der senoablative NK-Zellen bei der Krankheitsprogression hervor.
Die Forschung betont die Bedeutung der Aufrechterhaltung der NK-Zellfunktion für ein gesundes Altern und diskutiert das Potenzial der adoptiven NK-Zelltherapie zur Bekämpfung der Immunoseneszenz. Der klinische Kandidat des Unternehmens, CYNK-001, eine von der Plazenta abgeleitete allogene NK-Zelltherapie, wurde an über 70 Probanden mit akzeptablen Sicherheitsprofilen untersucht. Die Therapie zielt darauf ab, seneszente Zellen zu eliminieren, die toxische Zytokine freisetzen, die Entzündungen und bösartige Transformationen fördern, was potenziell Bedingungen wie altersbedingte Gebrechlichkeit und Sarkopenie zugutekommen könnte.
- Clinical candidate CYNK-001 demonstrated acceptable safety profile in 70+ subjects
- Publication in prestigious peer-reviewed journal validates scientific approach
- Therapy shows potential applications in multiple conditions (cancer, viral infections, age-related diseases)
- No efficacy data or clinical outcomes reported from the trials
- Research remains in clinical-stage without commercial products
Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases
FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced a key publication in the April 4, 2025, issue of the prestigious peer-reviewed journal Frontiers in Immunology, the official journal of the International Union of Immunological Societies.
In “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease,” Celularity scientists discuss how aging may influence the battle between the immune system and cancer, and the implications of senoablative Natural Killer, or NK, cells in disease progression. They emphasize that “preserving the function of NK cells during aging is essential for promoting healthy aging and longevity.” They conclude the publication by discussing the potential of adoptive NK cell therapy as a countermeasure to age-related decline in immunological function, a condition called immunosenescence.
Robert J. Hariri, M.D., Ph.D., a publication coauthor and Celularity Chairman and CEO, observed, “NK cell-based therapies demonstrate promise not only in treating cancer and viral infections but also a key role in rejuvenating the aging immune system, by eliminating senescent cells. This process, which we term “senoablation,” kills and clears senescent cells that exhibit a senescence-associated secretory phenotype (SASP), releasing toxic cytokines that promote inflammation and malignant transformation. Aside from the release of these toxic cytokines, senescent cells that remain in tissues block functional regeneration by healthy normal cells. We believe that eliminating these senescent cells could mitigate some of the negative effects of aging and offer clinical benefits in conditions such as age-related frailty and sarcopenia. Our clinical-stage, placental-derived allogeneic NK cell investigational candidate, CYNK-001, has been studied in over 70 subjects with acceptable safety and may represent a promising approach to addressing a range of conditions driven by cellular senescence.”
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit www.celularity.com.
Forward Looking Statements
This press release includes “forward-looking statements” (as defined under Federal securities laws). All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,” and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 30, 2024, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
FAQ
What is the significance of Celularity's CYNK-001 clinical trial results?
How does Celularity's NK cell therapy CYNK-001 work against aging?
What conditions could Celularity's CYNK-001 potentially treat?
What are the key findings of Celularity's April 2025 Frontiers in Immunology publication?
